ReviewOncotarget2026
Emerging biomedical imaging applications of tumor-derived extracellular vesicles for premetastatic niche detection: Biological rationale, engineering strategies, and translational challenges.
Review in Oncotarget, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Copyright: © 2026 Dhaygude et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Extracellular vesicles (EVs) are a heterogeneous population of membrane-enclosed nanoparticles naturally released by virtually all cell types, including exosomes, microvesicles, and other vesicular subtypes that differ in biogenesis, size, and molecular composition. By transporting proteins, lipids, nucleic acids, and metabolites, EVs mediate local and systemic intercellular communication and play a central role in tumor progression, organ-specific metastasis, and remodeling of distant microenvironments. Recent advances in EV isolation, engineering, and molecular profiling have accelerated interest in their use as nanomedicine platforms for both targeted delivery and cancer diagnostics. In particular, tumor-derived EVs (TEVs) exhibit intrinsic organotropism and participate in the establishment of premetastatic niches, making them promising vehicles for the targeted delivery of imaging probes to metastasis-prone tissues. This review discusses the emerging use of EVs as carriers of contrast and molecular imaging agents to enable visualization of premetastatic niches before overt metastatic lesions become detectable by conventional imaging modalities such as computed tomography. We highlight the biological rationale, engineering strategies, imaging applications, and translational challenges associated with EV-based probe delivery and consider how this approach may improve early detection of metastatic spread, risk stratification, and disease monitoring in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.